AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34284726 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic band resistance training (3 times per week for 12 weeks)
Number of subjects: 63
Study 32038011 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair with omentoplasty (16 patients, 80%)
Number of subjects: 20
Study 32038011 — intervention group
Group type: COMPARATOR
Intervention: Open repair (4 patients, 20%)
Number of subjects: 20
Study 35609292 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization within 0-30 minutes
Number of subjects: 0
Study 35609292 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization within 31-60 minutes
Number of subjects: 0
Study 35609292 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization within 61-90 minutes
Number of subjects: 0
Study 35609292 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization within 91-120 minutes
Number of subjects: 0
Study 33607803 — intervention group
Group type: EXPERIMENTAL
Intervention: therapy of 'combination 3 methods progression'
Number of subjects: 60
Study 33607803 — intervention group
Group type: COMPARATOR
Intervention: usual rehabilitation care
Number of subjects: 60
Study 32703182 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluteal turnover flap
Number of subjects: 160
Study 32703182 — intervention group
Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 160
Study 35451636 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced diuresis using furosemide 1 mg/kg (GII)
Number of subjects: 148
Study 35451636 — intervention group
Group type: COMPARATOR
Intervention: Control group (GI)
Number of subjects: 148
Study 32049634 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy total diet replacement (TDR)
Number of subjects: 90
Study 32049634 — intervention group
Group type: COMPARATOR
Intervention: Standardized dietetic care
Number of subjects: 90
Study 33113211 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST) 2 days/week at 90% 1RM for 12 weeks
Number of subjects: 48
Study 33113211 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) received two introductory training sessions and encouragement to train independently
Number of subjects: 48
Study 33113211 — intervention group
Group type: COMPARATOR
Intervention: Both TG and CG
Number of subjects: 48
Study 32937837 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (no treatment)
Number of subjects: 120
Study 32937837 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (antibiotics before implantation)
Number of subjects: 120
Study 32937837 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (implants after functional endoscopic sinus surgery)
Number of subjects: 120
Study 32937837 — intervention group
Group type: COMPARATOR
Intervention: MOD (distance between maxillary sinus ostium and sinus floor)
Number of subjects: 120
Study 35477616 — intervention group
Group type: EXPERIMENTAL
Intervention: REL-1017 25 mg
Number of subjects: 62
Study 35477616 — intervention group
Group type: EXPERIMENTAL
Intervention: REL-1017 50 mg
Number of subjects: 62
Study 35477616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 34463696 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-normal Pao2 target (8 to 12 kPa), n = 205
Number of subjects: 574
Study 34463696 — intervention group
Group type: COMPARATOR
Intervention: High-normal Pao2 target (14 to 18 kPa), n = 195
Number of subjects: 574
Study 35145043 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day bismuth-based quadruple therapy (n=102)
Number of subjects: 782
Study 35145043 — intervention group
Group type: COMPARATOR
Intervention: 14-day metronidazole-intensified triple therapy (n=99)
Number of subjects: 782
Study 35145043 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness
Number of subjects: 782
Study 35130447 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible clinical trial designs
Number of subjects: 0
Study 35130447 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-clinical screening of drugs
Number of subjects: 0
Study 35130447 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel compounds
Number of subjects: 0
Study 32063382 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse childhood experiences (ACE) survey
Number of subjects: 1760
Study 32063382 — intervention group
Group type: EXPERIMENTAL
Intervention: Household dysfunction
Number of subjects: 1760
Study 32063382 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse childhood experiences
Number of subjects: 1760
Study 32063382 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-harming behaviours
Number of subjects: 1760
Study 32274489 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal postoperative instructions
Number of subjects: 150
Study 32274489 — intervention group
Group type: EXPERIMENTAL
Intervention: Written postoperative instructions
Number of subjects: 150
Study 32274489 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal plus written postoperative instructions
Number of subjects: 150
Study 33051255 — intervention group
Group type: COMPARATOR
Intervention: Low-dose SCS (initial dose ≤ 40 mg prednisone equivalent/d)
Number of subjects: 1375
Study 33051255 — intervention group
Group type: COMPARATOR
Intervention: Medium-dose SCS (initial dose = 40-100 mg prednisone equivalent/d)
Number of subjects: 1375
Study 33051255 — intervention group
Group type: COMPARATOR
Intervention: High-dose SCS (initial dose > 100 mg prednisone equivalent/d)
Number of subjects: 1375
Study 32175588 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to PM2.5
Number of subjects: 20874
Study 34579127 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) combined with EPO and Iron Sulfate; 24 weeks/3 days per week at moderate intensity of full-body resistance exercises
Number of subjects: 157
Study 34579127 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTL) without iron treatment (CTL-none); n = 19
Number of subjects: 157
Study 34579127 — intervention group
Group type: COMPARATOR
Intervention: Control group treated only with iron sulfate or EPO (CTL-EPO or IRON); n = 19
Number of subjects: 157
Study 34579127 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with both iron sulfate and EPO (CTL-EPO + IRON); n = 76
Number of subjects: 157
Study 34579127 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training group without iron treatment (RT-none); n = 20
Number of subjects: 157
Study 34579127 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training group treated only with iron sulfate or EPO (RT-EPO or IRON); n = 18
Number of subjects: 157
Study 34579127 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training group treated with both iron sulfate and EPO (RT-EPO + IRON); n = 86
Number of subjects: 157
Study 36154566 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced prenatal care models with social support
Number of subjects: 77
Study 36154566 — intervention group
Group type: COMPARATOR
Intervention: COVID-19-related stressors (childcare and tension at home)
Number of subjects: 77
Study 34495078 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) consisting of 3 weekly sessions of aerobic exercise, resistance exercises, and flexibility (72 sessions over 40±3.9 weeks)
Number of subjects: 44
Study 34495078 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 individuals)
Number of subjects: 44
Study 32814123 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) machine for 2 × 15 min per session plus routine exercises for 1 h, three times a week for 4 weeks
Number of subjects: 21
Study 32814123 — intervention group
Group type: COMPARATOR
Intervention: Routine exercises for 1 h, three times a week for 4 weeks
Number of subjects: 21
Study 36114553 — intervention group
Group type: EXPERIMENTAL
Intervention: Space creation with an orthodontic appliance, removal of the supernumerary tooth and application of direct orthodontic traction
Number of subjects: 0
Study 36114553 — intervention group
Group type: COMPARATOR
Intervention: Space creation with an orthodontic appliance, removal of the supernumerary tooth and monitoring
Number of subjects: 0
Study 36114553 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 33618680 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator guided training
Number of subjects: 54
Study 33618680 — intervention group
Group type: COMPARATOR
Intervention: Tutor guided training
Number of subjects: 54
Study 32100297 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconsultation (TC) follow-up
Number of subjects: 110
Study 32100297 — intervention group
Group type: COMPARATOR
Intervention: Hospital follow-up
Number of subjects: 110
Study 35661801 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day time-restricted feeding
Number of subjects: 8
Study 35661801 — intervention group
Group type: COMPARATOR
Intervention: Control trial
Number of subjects: 8
Study 33154086 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Directly Observed Therapy (R‐DOT)
Number of subjects: 35
Study 33154086 — intervention group
Group type: EXPERIMENTAL
Intervention: Hailie Smartinhaler
Number of subjects: 35
Study 33154086 — intervention group
Group type: EXPERIMENTAL
Intervention: INhaler Compliance Assessment device (INCA)
Number of subjects: 35
Study 33154086 — intervention group
Group type: EXPERIMENTAL
Intervention: Rafi‐tone App
Number of subjects: 35
Study 33154086 — intervention group
Group type: EXPERIMENTAL
Intervention: NEMD (general)
Number of subjects: 35
Study 34340097 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg rectal, administered twice within the same day, starting at twelve hours after triggering)
Number of subjects: 214
Study 34340097 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 214
Study 34340097 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 214
Study 33396257 — intervention group
Group type: EXPERIMENTAL
Intervention: Serve training after tennis training (ATS)
Number of subjects: 25
Study 33396257 — intervention group
Group type: COMPARATOR
Intervention: Serve training before tennis training (BTS)
Number of subjects: 25
Study 35961468 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene and Education (SHE)
Number of subjects: 0
Study 35961468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT–I)
Number of subjects: 0
Study 35961468 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT)
Number of subjects: 0
Study 35961468 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT–I + BLT combined and simultaneously delivered
Number of subjects: 0
Study 35961468 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33347632 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CGRP monoclonal antibodies
Number of subjects: 14
Study 32988690 — intervention group
Group type: EXPERIMENTAL
Intervention: CoVER curriculum (four online modules and an in-person training guide)
Number of subjects: 1444
Study 32988690 — intervention group
Group type: COMPARATOR
Intervention: Control (standard vaccine education)
Number of subjects: 1444
Study 32988690 — intervention group
Group type: EXPERIMENTAL
Intervention: CoVER curriculum
Number of subjects: 1444
Study 35157096 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy with abdominal mesh attachment (TLH)
Number of subjects: 314
Study 35157096 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy with vaginal mesh attachment (TVH)
Number of subjects: 314
Study 35157096 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TLH and TVH)
Number of subjects: 314
Study 34154363 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics supplementation combined with WeChat platform health management
Number of subjects: 150
Study 34154363 — intervention group
Group type: COMPARATOR
Intervention: Routine follow‐up (Control group)
Number of subjects: 150
Study 33068343 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of abdominal moxibustion from 7 am to 9 am and rehabilitation training
Number of subjects: 100
Study 33068343 — intervention group
Group type: COMPARATOR
Intervention: Control group with basic treatment of internal medicine and rehabilitation training
Number of subjects: 100
Study 35281612 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy shockwave therapy (ESWT)
Number of subjects: 42
Study 35281612 — intervention group
Group type: COMPARATOR
Intervention: Routine physical therapy (RPT)
Number of subjects: 42
Study 32024497 — intervention group
Group type: EXPERIMENTAL
Intervention: Human infection studies (HIS)
Number of subjects: 26
Study 32024497 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditions for acceptability of HIS
Number of subjects: 26
Study 32024497 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder perceptions
Number of subjects: 26
Study 32024497 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing assessment
Number of subjects: 26
Study 36378691 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent (DTS)
Number of subjects: 3146
Study 36378691 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting Orsiro stent (O-SES)
Number of subjects: 3146
Study 34326921 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu granules
Number of subjects: 0
Study 34326921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32517188 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acid (PUFA)‐rich breakfast
Number of subjects: 60
Study 32517188 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid (MUFA)‐rich breakfast
Number of subjects: 60
Study 32517188 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acid (SFA)‐rich breakfast
Number of subjects: 60
Study 36150356 — intervention group
Group type: EXPERIMENTAL
Intervention: PDMP alert for high dose
Number of subjects: 241
Study 36150356 — intervention group
Group type: EXPERIMENTAL
Intervention: PDMP alert for multiple prescriber episodes
Number of subjects: 241
Study 36150356 — intervention group
Group type: EXPERIMENTAL
Intervention: PDMP alerts
Number of subjects: 241
Study 36150356 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient and medication characteristics (age, opioid dose, benzodiazepine use, co-morbidity)
Number of subjects: 241
Study 33610904 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 478
Study 32892222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibezapolstat
Number of subjects: 62
Study 32892222 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 62
Study 33273275 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 weeks of multifaceted physiotherapy
Number of subjects: 197
Study 33273275 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list controls
Number of subjects: 197
Study 32415846 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (400 mg/day for 8 weeks, then tapered)
Number of subjects: 21
Study 32415846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 32415846 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 21
Study 32825982 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 45
Study 32825982 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training with Curcumin Supplement (RTC)
Number of subjects: 45
Study 32825982 — intervention group
Group type: COMPARATOR
Intervention: Curcumin Supplement (C)
Number of subjects: 45
Study 32825982 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 45
Study 35564909 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustainability Action Plan (SAP) for the SAGE intervention
Number of subjects: 0
Study 35564909 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory research (CBPR) approach
Number of subjects: 0
Study 34250690 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 63
Study 34250690 — intervention group
Group type: EXPERIMENTAL
Intervention: EFIC procedures
Number of subjects: 63
Study 34250690 — intervention group
Group type: COMPARATOR
Intervention: No EFIC procedures
Number of subjects: 63
Study 34657779 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐Clinician Shared Decision‐Making (FCSDM) intervention
Number of subjects: 548
Study 34657779 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 548
Study 34509883 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide
Number of subjects: 138
Study 34509883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 35668423 — intervention group
Group type: EXPERIMENTAL
Intervention: SAIA-MH (multicomponent implementation strategy)
Number of subjects: 16
Study 35668423 — intervention group
Group type: COMPARATOR
Intervention: Attentional placebo control
Number of subjects: 16
Study 35353055 — intervention group
Group type: EXPERIMENTAL
Intervention: TangPlan and WeChat
Number of subjects: 156
Study 34127624 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbosacral orthosis (LSO) plus routine physical therapy for 3 weeks
Number of subjects: 24
Study 34127624 — intervention group
Group type: COMPARATOR
Intervention: Routine physical therapy alone for 3 weeks
Number of subjects: 24
Study 33032908 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 600 mg for 80 days
Number of subjects: 0
Study 33032908 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 80 days
Number of subjects: 0
Study 35998119 — intervention group
Group type: EXPERIMENTAL
Intervention: Domagrozumab
Number of subjects: 120
Study 35998119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 34272972 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 382
Study 34272972 — intervention group
Group type: COMPARATOR
Intervention: Control (no DA use)
Number of subjects: 382
Study 33219117 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise group (EG, n=146)
Number of subjects: 1072
Study 33219117 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise prescription group (PG, n=144)
Number of subjects: 1072
Study 33219117 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON, n=782)
Number of subjects: 1072
Study 35277402 — intervention group
Group type: EXPERIMENTAL
Intervention: DLPFC-rTMS
Number of subjects: 50
Study 35277402 — intervention group
Group type: COMPARATOR
Intervention: M1-rTMS
Number of subjects: 50
Study 33896706 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based cardiovascular risk reduction program using the 'BreastMate' application as an adjunct to standard care.
Number of subjects: 0
Study 33896706 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 0
Study 33896706 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based cardiovascular risk reduction program.
Number of subjects: 0
Study 33144481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Number of subjects: 76
Study 33144481 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study 36417312 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 72
Study 36417312 — intervention group
Group type: COMPARATOR
Intervention: Open colorectal surgery
Number of subjects: 72
Study 36417312 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies
Number of subjects: 72
Study 36417312 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of surgical trainees
Number of subjects: 72
Study 34324880 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral iron supplementation (mean 4.8 mg/kg/d in Epo group, 3.6 mg/kg/d in placebo group) at 60 days
Number of subjects: 692
Study 34324880 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mean 3.6 mg/kg/d) at 60 days
Number of subjects: 692
Study 34324880 — intervention group
Group type: EXPERIMENTAL
Intervention: Epo (mean 4.8 mg/kg/d) at 60 days
Number of subjects: 692
Study 34324880 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron dose at 90 days
Number of subjects: 692
Study 32918513 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcultural psychotherapy (TCP) - six sessions in addition to usual care
Number of subjects: 80
Study 32918513 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study 35691568 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg empagliflozin
Number of subjects: 0
Study 35691568 — intervention group
Group type: COMPARATOR
Intervention: 10 mg empagliflozin
Number of subjects: 0
Study 33298149 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins at 50 IU anti-Xa/kg twice daily or 75 IU anti-Xa twice daily in combination with aprotinin
Number of subjects: 0
Study 33298149 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins with aprotinin and anakinra (if hyperinflammation is present)
Number of subjects: 0
Study 33298149 — intervention group
Group type: COMPARATOR
Intervention: Standard thromboprophylaxis
Number of subjects: 0
Study 33757380 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) treatment
Number of subjects: 98
Study 33757380 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 98
Study 35707984 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula Therapy (HFNC)
Number of subjects: 573
Study 35707984 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure Therapy (CPAP)
Number of subjects: 573
Study 33749321 — intervention group
Group type: EXPERIMENTAL
Intervention: OB-002H gel (5 vaginal daily doses)
Number of subjects: 30
Study 33749321 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (5 vaginal daily doses)
Number of subjects: 30
Study 33749321 — intervention group
Group type: EXPERIMENTAL
Intervention: OB-002H gel
Number of subjects: 30
Study 32291608 — intervention group
Group type: EXPERIMENTAL
Intervention: Congrong Shujing Granules (CSGs) combined with Western medicine (WM)
Number of subjects: 72
Study 32291608 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with Western medicine (WM)
Number of subjects: 72
Study 34964489 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated algorithm for B-line detection and quantification
Number of subjects: 80